COO COOPER COMPANIES, INC.
Ophthalmic Goods · Nasdaq · SEC CIK 711404 · Fiscal year ends 10/31
Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.7%
TTM net income YoY39.8%
TTM EPS YoY42.6%
Revenue 3-yr CAGR6.4%
Net income 3-yr CAGR27.5%
Margins
Gross margin65.9%
Operating margin12.8%
Net margin13.5%
FCF margin16.0%
EBITDA margin19.7%
Returns
ROE6.8%
ROA4.6%
ROIC (approx.)5.1%
Asset turnover0.34x
Leverage & solvency
Liabilities / assets34.3%
Debt / equity0.31x
Current ratio1.22x
Interest coverage6.10x
Cash quality & payout
Operating cash flow / net income1.81x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue8.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-10-31 | FY20242024-10-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.09B | $3.90B |
| Cost of revenue | $1.41B | $1.30B |
| Gross profit | $2.68B | $2.60B |
| R&D expense | $172.20M | $155.10M |
| SG&A expense | $1.63B | $1.53B |
| Operating income | $682.90M | $705.70M |
| Interest expense | $100.00M | $114.30M |
| Pretax income | $566.50M | $582.30M |
| Income tax | $191.60M | $190.00M |
| Net income | $374.90M | $392.30M |
| EBITDA | $1.06B | $1.08B |
| EPS (basic) | 1.88 | 1.97 |
| EPS (diluted) | 1.87 | 1.96 |
| Weighted avg. shares (diluted) | 200.00M | 200.40M |
| Balance sheet | ||
| Cash & equivalents | $110.60M | $107.70M |
| Receivables | $829.00M | $717.00M |
| Inventory | $846.00M | $802.70M |
| Current assets | $2.11B | $1.95B |
| PP&E, net | $2.08B | $1.86B |
| Goodwill | $3.85B | $3.84B |
| Intangibles | $1.59B | $1.79B |
| Total assets | $12.39B | $12.32B |
| Current liabilities | $1.11B | $1.02B |
| Short-term debt | $47.80M | $33.30M |
| Long-term debt | $2.46B | $2.55B |
| Total debt | $2.50B | $2.58B |
| Total liabilities | $4.16B | $4.23B |
| Shareholders' equity | $8.24B | $8.08B |
| Net debt | $2.39B | $2.47B |
| Shares outstanding | 195.90M | 199.60M |
| Cash flow statement | ||
| Operating cash flow | $796.10M | $709.30M |
| Capital expenditure | $362.40M | $421.20M |
| Free cash flow | $433.70M | $288.10M |
| Investing cash flow | -$372.90M | -$764.60M |
| Financing cash flow | -$425.90M | $39.20M |
| Depreciation & amortization | $377.40M | $375.10M |
| Stock-based compensation | $70.50M | $75.10M |
| Dividends paid | $0 | $0 |
| Share buybacks | $290.10M | $0 |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.